Abstract | RATIONALE: PATIENT CONCERNS: The patient with systemic lupus erythematosus (SLE) had an uncommon combination of intermittent fever, hyperferritinemia, hypertriglyceridemia, jaundice, and significantly abnormal liver function test results. The patient reported a history of daily fever of 38 to 39°C, painful oral ulcer, anorexia, abdominal bloating, diarrhea, and malar rash progression for 2 weeks, and jaundice, tea-colored urine, and clay-colored stool for 1 week preceding hospital admission. DIAGNOSIS: INTERVENTIONS: OUTCOMES: After dexamethasone 15 mg q8 h treatment, the patient's fever subsided within 2 days, and liver function became normal within 3 weeks. The patient regularly attended scheduled outpatient follow-up visits after discharge. After 2 years, the patient reported no symptoms or signs of SLE with 2 mg/d oral dexamethasone. LESSONS: Early diagnosis of MAS and dexamethasone treatment for MAS with ARDS appear to be crucial for these patients.
|
Authors | En-Shuo Chang, Han-Hua Yu, Chiao-En Wu, Tien-Ming Chan |
Journal | Medicine
(Medicine (Baltimore))
Vol. 101
Issue 5
Pg. e28612
(Feb 04 2022)
ISSN: 1536-5964 [Electronic] United States |
PMID | 35119005
(Publication Type: Case Reports, Journal Article, Review)
|
Copyright | Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. |
Chemical References |
- Antirheumatic Agents
- Cytokines
- Interleukin 1 Receptor Antagonist Protein
- Dexamethasone
- Methylprednisolone
|
Topics |
- Antirheumatic Agents
(therapeutic use)
- Cytokine Release Syndrome
- Cytokines
- Dexamethasone
(therapeutic use)
- Humans
- Interleukin 1 Receptor Antagonist Protein
(therapeutic use)
- Lupus Erythematosus, Systemic
(complications, drug therapy)
- Macrophage Activation Syndrome
(drug therapy, etiology)
- Methylprednisolone
(therapeutic use)
- Respiratory Distress Syndrome
(drug therapy, etiology)
|